CTRI/2012/05/002666招募中1 期
A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents with Type 3 Gaucher Disease
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Each patient must meet the following criteria to be enrolled in this study.
- •1.The patient has a confirmed diagnosis of type 3 Gaucher disease.
- •2.The patient is >=2 and <18 years of age at the time of enrollment.
- •3. The patient is either naive to treatment or has not received treatment (investigational or approved) for gaucher disease within 12 months prior to study entry.
- •4.The patient has Gaucher disease-related anemia, defined as hemoglobin concentration below the lower limit of normal for age and sex.
- •AND ONE OR MORE OF THE FOLLOWING THREE CRITERIA
- •a.The patient has at least moderate splenomegaly (2 to 3 cm below the left costal margin) by palpation.
- •b.The patient has Gaucher disease-related thrombocytopenia, defined as platelet count less than120 multiply to 1000 platelets/mm3.
- •c.The patient has a Gaucher disease-related readily palpable enlarged liver.
- •5.Patients who have undergone splenectomy may still be eligible to participate in the study.
- •6.Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study. Pregnancy testing will be performed at the time of enrollment and as required throughout participation in the study. Male patients must agree to use a medically acceptable method of contraception at all times during the study and report a partnerâ??s pregnancy to the Investigator.
- •7.The patientâ??s parent(s) or the patientâ??s legally authorized representative(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
排除标准
- •Patients who meet any of the following criteria will be excluded from this study.
- •1.The patient is suspected of having type 2 or type 1 Gaucher disease.
- •2. The patient is less than 2 years of age.
- •3.The patient has experienced a severe (Grade 3 or higher) infusion-related hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any enzyme replacement therapy for Gaucher disease (approved or investigational).
- •4.The patient has received any non-Gaucher disease-related treatment with an investigational drug within 30 days prior to study entry.
- •5.The patient is a pregnant and/or lactating female.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher DiseaseType 3 Gaucher diseaseMedDRA version: 18.1Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003427-38-Outside-EU/EEAShire Human Genetic Therapies6
进行中（未招募）
不适用
?A study to check how beneficial and safe the drug canakinumab is for patients with TNF-receptor associated periodic syndrome (TRAPS)TNF-receptor associated periodic syndrome (TRAPS)MedDRA version: 14.1Level: LLTClassification code 10067783Term: Tumor necrosis factor receptor-associated periodic syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-020061-24-IEovartis Pharma Services AG20
进行中（未招募）
1 期
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long term treatment period in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - D2203TNF-receptor associated periodic syndrome (TRAPS)MedDRA version: 16.1 Level: LLT Classification code 10067783 Term: Tumor necrosis factor receptor-associated periodic syndrome System Organ Class: 100000004850EUCTR2010-020061-24-GBovartis Pharma Services AG20
进行中（未招募）
不适用
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - NDActive recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS)MedDRA version: 12.1Level: LLTClassification code 10034533Term: Periodic feverEUCTR2010-020061-24-ITOVARTIS FARMA50
已完成
4 期
THETIS- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemiaon-transfusion Dependent ThalassemiaNon-transfusion Dependent ThalassemiaD56.9LBCTR2020011375ovartis Pharmaceuticals20